		Technical Data
A0196-01C	ACSL5, NT (Long-chain-fatty-acid-CoA Ligase 5, Long-chain Acyl-CoA Synthetase 5, LACS 5, ACS5, FACL5, UNQ633/PRO1250)

Description:
Long chain acyl-CoA synthetase (LACS), or long chain fatty acid-CoA ligases (FACLs), convert free long chain fatty acids into fatty acyl-CoA esters, which are key intermediates in the synthesis of complex lipids. The deduced 683aa FACL5 protein shares approximately 80% amino acid identity with the rat sequence. Northern blot analysis detected major FACL5 transcripts of 2.5 and 3.7 kb in a many tissues, with highest expression in uterus and spleen. Markedly increased levels of FACL5 transcripts are detected in a glioma line and in primary gliomas of grade IV malignancy, Cultured glioma cells infected with an adenovirus encoding FACL5 displayed induced cell growth on exposure to palmitate. These results suggest a novel fatty acid-induced glioma cell growth mediated by FACL5.

Applications:
Suitable for use in ELISA, Western Blot, and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
ELISA: 1:1,000
Western Blot: 1:50-1:200
Immunohistochemistry: 1:50-1:100
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Type	Isotype	Clone	Grade
Pab	IgG		Affinity Purified

Size		Storage	Shipping	Source	Host
100ug		-20°C	Blue Ice	Human	Rabbit

Concentration:

~0.25mg/ml

Immunogen:

Synthetic peptide selected from the N-terminal region of of human FACL5 (KLH).

Purity:

Purified by Protein G affinity chromatography.

Form

Supplied as a liquid in PBS, 0.09% sodium azide.

Specificity:

Recognizes human FACL5. Species Crossreactivity: mouse.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

1.Clark, H.F., et al., Genome Res. 13(10):2265-2270 (2003). 2.Yamashita, Y., et al., Oncogene 19(51):5919-5925 (2000). 3.Minekura, H., et al., Gene 278(1-2), 185-192 (2001).